Page 10 - மருந்துப்போலி கட்டுப்படுத்தப்படுகிறது படிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients - 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p 0.001)[1] - All ranked secondary endpoints were met[1] - These results reaffirm findings from the first Phase 3 induction study, U-ACHIEVE[1,2] - Safety results were consistent with the previous Phase 3 induction study and the known profile of upadacitinib, with no new safety risks observed[1-6] - Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral therapy for moderate to severe ulcerative colitis and several other immune-mediated diseases[1,7-14]

United statesUpadacitinib monotherapyAccess economics ptyEuropean academy of dermatologyAbbvie incVenerology congressClinical programUpadacitinib ulcerative colitis programDrug administrationEuropean commissionExchange commissionCrohn colitis foundation of americaAdapted mayo scoreAdapted mayoUpadacitinib ulcerative colitisSafety information